Haemonetics (HAE) stock jumps as CSL (CSLLY) plans to use the company's devices across all of its plasma collection centers ...
CSL trades at a discount despite owning a dominant, hard-to-replicate global plasma-derived therapies infrastructure. Transformation Program targets $500–$550M in annual pre-tax cost reductions by ...
CSL will outlay $1.5bn over the next five years in the US to grow its footprint of plasma therapy production, the latest pharma company to pour money into the country amid tariff threats.
Global biopharmaceutical company CSL announced a significant expansion of its United States operations, committing approximately US$1.5 billion in new capital investments over the next five years to ...
CSL: Facing Headwinds but Shares Undervalued as We Expect Resilient Plasma Demand and Margins ...
Illinois Gov. JB Pritzker on Monday announced a $1.5 billion investment from biotherapeutics company CSL for a new plasma therapy manufacturing plant in Kanakee. CSL will expand its current footprint ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results